Company Description
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction.
The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition.
Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 97 |
| CEO | Faraz Ali |
Contact Details
Address: 171 Oyster Point Boulevard, Suite 500 South San Francisco, California 94080 United States | |
| Phone | 650 825 6990 |
| Website | tenayatherapeutics.com |
Stock Details
| Ticker Symbol | TNYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001858848 |
| CUSIP Number | 87990A106 |
| ISIN Number | US87990A1060 |
| Employer ID | 81-3789973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Faraz Ali M.B.A. | Chief Executive Officer, Interim Principal Financial Officer and Director |
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Bruce R. Conklin M.D. | Scientific Founder |
| Dr. Saptarsi Haldar M.D. | Scientific Founder |
| Dr. Sheng Ding Ph.D. | Scientific Founder |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder |
| Tomohiro Higa M.B.A. | Senior Vice President of Finance and Interim Principal Accounting Officer |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2025 | SCHEDULE 13G/A | Filing |
| May 30, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G | Filing |
| May 14, 2025 | SCHEDULE 13D/A | Filing |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| May 7, 2025 | SCHEDULE 13G | Filing |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 17, 2025 | ARS | Filing |
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |